Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Gantenerumab G4 vs G3 in Healthy Volunteers
NCT03236844Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gantenerumab in Alzheimer's disease (AD) (2 arms), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration at Day 85 and Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time at Day 85. Started Aug 2017; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03236844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236844.